MakCHS Funding Opportunities as at 10th October 2023
Please find attached the New Funding Opportunities from different funders.
Should there be interest in, and commitment to pursuing a particular listed and/or otherwise self-identified funding opportunity, please contact:
Tayebwa.Mordecai *(tayebwa.mordecai@gmail.com <tayebwa.mordecai@gmail.com>*),
Melissa. Nakiyaga *(**melissa.nakiyaaga@mak.ac.ug <melissa.nakiyaaga@chs.mak.ac.ug>*) and
Tusiime Boniconsilli (bonny.tusiime@mak.ac.ug <tusiime.bonny@chs.mak.ac.ug>)* for the related planning, coordination, writing, and budgeting efforts.
We welcome any other opportunities you may be aware of that are not included in this list.
MaKCHS Funding Opportunities Revised Final 10.10.2023
| Makerere University College of Health Sciences_Funding Opportunity Announcements 2023 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | FOA title | Description | Funding Amount | Funding Period | Funder | Application due date | Letter of intent due date | Link | |||
| 1 | Improved prediction, detection, and treatment approaches for comprehensive stroke management | Globally, stroke is the second leading cause of death and the third leading cause of disability. One in four people are in danger of stroke in their lifetime. In Europe in 2017, nearly 1.5 million people suffered a stroke, nine million Europeans lived with a stroke, and more than 430,000 people died due to a stroke. The total cost of stroke in that year was €60 billion. The number of new strokes and the number of people living with stroke is set to rise due to the aging population of Europe, as age is the greatest, non-modifiable risk factor for stroke. The challenge in stroke management is the lack of efficient and comprehensive pathways along the whole continuum of the disease – including the variation of structural settings depending on the location of the patient (rural vs. central) and between countries. While several effective treatment approaches are available, there are still silos existing between the different stages of care (e.g., primary, acute care, intensive care, chronic hospitalization, and rehabilitation). The implementation of connected healthcare pathways will lead to an improvement in the outcome for the patients and thereby drive efficiency and effectiveness from a clinical and health resource perspective. | EURO 12,000,000 | Not specified | European Commission | 16-Jan-24 | Not Applicable | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-ju-ihi-2023-05-03;callCode=HORIZON-JU-IHI-2023-05;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;progr | |||
| 2 | Maximising the potential of synthetic data generation in healthcare applications | According to European Commission, the proposals should contribute to: academic and industrial researchers who should have access to relevant, robust, and generalizable synthetic data generation methodologies including open source when relevant, to create and share pools of synthetic patient data in specific use cases, academic and industrial researchers should have access to relevant, high-quality synthetic datasets and thanks to better availability of robust synthetic datasets for training data models, healthcare providers and industry should have a wider range of performant AI-based and other data-driven tools to support diagnostics, personalized treatment decision-making and prediction of health outcomes. The scope is on Healthcare research using individual patient data which is often constrained due to restrictions in data access because of privacy, security, intellectual property (IP), and other concerns. Synthetic health data, i.e., data that is artificially created to mimic individual patient data, can reduce these concerns, leading to the more rapid development of reliable data-driven methods including diagnostic, precision medicine, decision support, and patient monitoring tools. However, while many synthetic data generation (SDG) methods are currently available, it is not always clear which method is best for which use case, and SDG methods for some types of data are still immature. Furthermore, it is still unclear whether highly detailed synthetic data, which are often needed for research, can be categorized as anonymous. | EURO 12,000,000 | Not specified | European Commission | 16-Jan-24 | Not Applicable | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-ju-ihi-2023-05-04;callCode=HORIZON-JU-IHI-2023-05;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;progr | |||
| 3 | Development and proof of principle of new clinical applications of theranostics solutions | The scope of this call according to the EU is on multi-modal theranostic solutions, currently dominated by radionuclide-based therapy and companion diagnostics, which are emerging as safe, personalized, and effective approaches for the treatment of several diseases. However, the use of such therapies is limited to a few specialized centers with the need to increase clinical treatment capacities and widen the arsenal of theranostics, possibly including novel non?nuclear approaches, e.g. enabled by nanotechnologies. To address this challenge, project(s) funded under this topic should aim at developing new, or innovative combinations of existing multi-modal theranostic solutions including radiopharmaceuticals and/or non-radioactive theranostic solutions. Applicants should clearly identify a disease(s) of unmet public health need, (e.g., oncology, neurology, and/or advanced multi-disease conditions) and explain their choice with relevant evidence where possible. | EURO 12,000,000 | Not specified | European Commission | 16-Jan-24 | Not Applicable | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-ju-ihi-2023-05-02;callCode=HORIZON-JU-IHI-2023-05;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1;statusCodes=31094501,31094502,31094503;progr | |||
| 4 | Translational Neural Devices (UG3/UH3 - Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Exploratory/Developmental Phased Award Cooperative Agreement. The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. | USD 1,500,000 per year | 5 years | National Institutes of Health (NIH) | October 18, 2023, February 20, 2024 | 60 days prior to the receipt date | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-021.html | |||
| 5 | Elucidating Variability of Physiologic and Functional Responses to Exercise Training in Older Adults (R01 Clinical Trial Required) | The National Institute on Aging (NIA) invites R01 applications that propose human studies to better understand factors underlying response variability to exercise training in older adults through this Notice of Funding Opportunity (NOFO). This NOFO encourages studies that identify systemic modulators, biomarkers, and other potential mechanisms underlying exercise variation in outcomes that are clinically relevant for older adults. Additionally, this NOFO encourages transdisciplinary studies utilizing innovative design methods and analytical approaches combined with clinical phenotyping to disentangle the complicated relationships between endogenous and exogenous factors that drive response variation to exercise. Elucidating factors and mechanisms that underlie variations in exercise response, and the extent to which these factors are modifiable, may enable more precise and efficacious exercise prescriptions to optimize the clinical efficacy of exercise training in older adults. | $1,000,000 | 5 years | National Institute of Health (NIH) | November 03, 2023 | October 03, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-045.html | |||
| 6 | Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed) | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs. | USD 900,000 | 3 years | National Institutes of Health (NIH) | February 08, 2024 | 8-Jan-24 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-027.html | |||
| 7 | Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional) | The purpose of this Notice of Funding Opportunity (NOFO) is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure. Specifically, this NOFOsolicits applications that will identify, understand, and develop strategies to address barriers to the adoption, integration, and sustainability of evidence-based cancer control interventions among PLWH in LMICs and generate data in LMICs that can inform effective and equitable implementation of evidence-based cancer control for PLWH worldwide. Responsive applications should include multi-disciplinary teams of researchers with expertise in HIV, cancer, and implementation science to address the cancer control needs of PLWH populations specific to the proposed LMIC context. | USD 500,000 per year | 5 years | National Institutes of Health (NIH) | December 15, 2023 | 30 days prior to the Application Due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-033.html | |||
| 8 | Engaging Survivors of Sexual Violence and Trafficking in HIV and Substance Use Disorder Services (R34 Clinical Trial Optional) | The goal of this notice of funding opportunity (NOFO) is to support exploratory research and preliminary interventions to address the interrelated and compounding contextual factors that contribute to substance use and HIV risk among survivors of sex trafficking. This would be accomplished through research that builds new interventions and models of care that can effectively engage survivors of sex trafficking in care for substance use disorder (SUD), HIV, trauma, and other mental health outcomes and addresses key structural and social determinants of health that contribute to risk for sexual trafficking, as well as barriers to and facilitators of escaping continued exploitation. | $450,000 | 3 years | National Institute of Health (NIH) | August 05, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-018.html | |||
| 9 | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed) | Through this funding opportunity announcement, the National Cancer Institute (NCI) intends to focus on the biological interactions of cancer health disparities in people living with HIV (PLWH) from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae. | $275,000 | 2 years | National Institute of Health (NIH) | December 15, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-057.html | |||
| 10 | BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) seeks the development of theories, computational models, and analytical tools to derive understanding of brain function from complex neuroscience data. Proposed projects could develop tools to integrate existing theories or formulate new theories; conceptual frameworks to organize or fuse data to infer general principles of brain function; multiscale/multiphysics models to generate new testable hypotheses to design/drive future experiments; new analytical methods to substantiate falsifiable hypotheses about brain function. It is expected that the tools developed under this FOA will be made widely available to the neuroscience research community for their use and modification. Investigative studies should be limited to model parameter estimation and/or validity testing of the tools being developed. | $250,000 | 3 years | National Institute of Health (NIH) | September 12, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-039.html | |||
| 11 | International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Required | The purpose of the International Research Scientist Development Award is to provide support and protected time to advanced postdoctoral U.S. research scientists and recently-appointed U.S. junior faculty for an intensive, mentored research career development experience in a low- or middle-income country (LMIC), as defined by the World Bank leading to an independently-funded research career focused on global health. | USD 75,000 | 3 years | National Institutes of Health (NIH) | 9-Mar-24 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-18-540.html | |||
| 12 | Four-year PhD Studentships in Science | This scheme offers graduates outstanding training in scientific research. | £88,756 | 4 years | Chosen programme | Up to 2024 | Not applicable | https://wellcome.org/grant-funding/schemes/four-year-phd-programmes-studentships-basic-scientists | |||
| 13 | Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed | The Fogarty HIV Research Training (HIVRT) Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program. This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial, but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor. | $28,000 per year | 2 years | National Institute of Health (NIH) | August 22, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-152.html | |||
| 14 | Master's Studentships in Humanities and Social Science | This scheme enables researchers to undertake humanities or social science Master's courses in any area of health. | £16,000 | 1 year | Chosen programme | Depends on the programme | Not applicable | https://wellcome.org/grant-funding/schemes/masters-studentships-humanities-and-social-science | |||
| 15 | Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed) | This Notice of Funding Opportunity (NOFO) aims to provide a proof-of-principle for a novel strategy for Alzheimer's disease (AD) and AD-related dementia (ADRD) immunotherapies. Specifically, the goal is to examine whether a novel immunotherapeutic approach in cancer immunotherapy with chimeric antigen receptor (CAR) immune cells can be customized as treatments for AD/ADRD. This NOFO utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase provides up to 2 years of support for initial developmental activities. The R33 phase provides up to 3 years of support for expanded activities. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 07, 2024 | January 07, 2024 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-046.html | |||
| 16 | BRAIN Initiative Cell Atlas Network (BICAN): Specialized Collaboratory on Human, Non-human Primate, and Mouse Brain Cell Atlases (U01 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) intends to support a group of Specialized Collaboratories that will adopt scalable technology platforms and streamlined sampling strategies and assay cascade to create comprehensive and highly granular brain cell atlases in human, non-human primates, mouse, and other species in coordination and collaboration with other BRAIN Initiative Cell Atlas Network (BICAN) projects. In particular, the Specialized Collaboratories are expected to complement the Comprehensive Centers in BICAN with distinct capabilities, competencies, and research aims. The overarching goal of the BICAN is to build reference brain cell atlases that will be widely used throughout the research community, providing a molecular and anatomical foundational framework for the study of brain function and disorders. | Application budgets are not limited | 3 years | National Institutes of Health (NIH) | February 01, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-292.html | |||
| 17 | Fulbright-Fogarty Fellowships In Public Health | The Fulbright English Teaching Assistant Program in Uganda aims to strengthen educational and cultural relationships between the United States and Uganda. It also provides a professional development opportunity for Americans to advance their teaching skills while living in Uganda. | Not Specified | 9 months | FULBright U.S Student Program | As per the FOA | Not applicable | https://us.fulbrightonline.org/applicants/types-of-awards/fulbright-fogarty-fellowships-in-public-health | |||
| 18 | Fulbright-Fogarty Public Health Fellowship Award | The Fulbright-Fogarty fellowship in Uganda offers U.S. post-graduate students in the health sciences practical experience designing and conducting clinical research in Uganda. | Not Specified | 9 months | FULBright U.S Student Program | As per the FOA | Not applicable | https://us.fulbrightonline.org/countries/sub-saharan-africa/uganda/1920 | |||
| 19 | Open Study/Research Award | The Fulbright U.S. Student Program in Uganda aims to strengthen educational and cultural relationships between the United States and Uganda. The Public Affairs Section of the U.S. Embassy in Kampala manages a small but vibrant Fulbright program that welcomes applications in a wide range of fields, including: area, ethnic, culture and gender studies; natural resources and conservation; the visual and performing arts; and the biological and biomedical sciences. Projects that support mission programs in health and education, as well as inclusive public institutions, and economic growth through improved access to domestic and international markets, strengthening democracy are especially encouraged. | Not Specified | 6-9 months | FULBright U.S Student Program | As per the FOA | Not applicable | https://us.fulbrightonline.org/countries/sub-saharan-africa/uganda/1575 | |||
| 20 | Gilead giving in Africa | Grant making in Africa focuses on HIV/AIDS and Viral Hepatitis. Within these therapeutic areas, we provide support for a broad range of activities, including disease awareness; disease prevention; professional education; improving patient access to care; improving quality of care; increasing scientific capacity; strengthening healthcare systems. Across the continent, Gilead works with a number of local partners to help ensure that our medicines reach the people that need them. Our pioneering generic licensing agreements have played a central role in expanding access to high-quality, low-cost HIV treatment throughout Africa. | Application budgets are not limited | Not specified | GILEAD | Grant applications are accepted throughout the year | Not applicable | https://www.gilead.com/purpose/giving/funding-requests/apply-africa | |||
| 21 | Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed) | Through this new funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to focus on basic mechanistic and translational studies using the R01 grant mechanism to investigate HIV and cancer in underrepresented groups. In the context of this FOA, underrepresented groups include racial, ethnic, and gender minorities, including underserved minorities living in geographical areas that have high numbers of new HIV infections (e.g., Southern and some urban areas in the United States, international sites that have higher rates of underlying HIV infection). Mechanistic and/or translational studies that examine how different comorbidities, associated behaviors, and other disorders (e.g., diabetes, smoking, injecting drug users, obesity, etc.), contribute to the initiation, progression and disease sequelae in underserved populations may be proposed. This initiative will increase our understanding of the role of HIV infection on cancer health disparities in these underserved populations. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | December 15, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-056.html | |||
| 22 | Earmarked scholarships scheme to support Category 1 project grants | Earmarked scholarships are funded by the Australian Government to assist PhD students with their living costs and tuition fees. These scholarships are offered for research projects aligned with recently awarded Category 1 research grants and offer PhD students the opportunity to contribute to large projects of national significance with and work with leading researchers. | USD 28,854 | 3.5 years | University of Queensland | 30-Dec-23 | Not applicable | https://scholarships.uq.edu.au/scholarship/earmarked-scholarships-support-category-1-project-grants | |||
| 23 | Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Clinical Trials Optional) | The purpose of this notice of funding opportunity (NOFO) is to solicit applications for research aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on substance use disorders (SUDs) and co-occurring psychiatric disorders in people living with HIV (PLWH). | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 15, 2024 | January 15, 2024 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-005.html | |||
| 24 | Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Basic Experimental Studies with Humans (BESH) Required) | The purpose of this notice of funding opportunity (NOFO) is to solicit applications for basic science experiments involving humans (BESH) aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on neurobehavioral function and risk for substance use disorders (SUD) and co-occurring psychiatric disorders in people living with HIV (PLWH). As referred to in NOT-OD-18-212, BESH are “prospective basic science studies involving human participants” that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Such studies prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental processes or principles. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 15, 2024 | January 15 , 2024 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-006.html | |||
| 25 | The Jane Coffin Childs Memorial Fund for Medical Research | The Jane Coffin Childs Memorial Fund for Medical Research (JCC Fund) was established by the Childs Family in 1937, to honor the memory of Jane Coffin Childs who died of cancer in 1936. Inspired by the founding purpose to support research into the causes and treatment of cancer, the Fund’s mission has broadened to support fundamental scientific research that advances understanding of the causes, treatments, and cures for human disease. The JCC Fund provides three years of salary support to the best and brightest postdoctoral fellows, as selected by the esteemed Board of Scientific Advisors (BSA), pursuing fundamental biomedical research to advance human health. Over 1,800 Jane Coffin Childs Fellows have been awarded to conduct basic cancer and human disease-related research in laboratories in North America, Europe, Japan and Australia. | $216,000 | 3 years | Jane Coffin Childs Memorial Fund for Medical Research | 1st February 2024 | Not applicable | https://www.jccfund.org/eligibilty-criteria/ | |||
| 26 | Inclusive Health Research (Award) | The Inclusive Health Research awards have been established by Nature Awards in partnership with Takeda to celebrate those who are driving a more inclusive approach to health research and, in doing so, promote a future of greater health equity globally. The Inclusive Health Research awards aim to: Uncover innovation and best practice in inclusive health research that has been influenced by engagement with affected communities and their expert representatives. Recognize, promote and support institutions and individuals who are contributing to a diverse, patient- and affected community-inclusive research ecosystem. Build a library of case studies to share — and encourage wider adoption of — new ideas and best practice in the co-production of research to advance global health equity. | EURO 20,000 | Not applicable | Springer Nature | 5th January 2024. | Not applicable | https://www.nature.com/immersive/inclusivehealthresearch/index.html#section-Home-dRg5aZzAXp | |||
| 27 | The Epilepsy Study Consortium Mini-grant | The Epilepsy Study Consortium is sponsoring a mini-grant of up to $22,000 for epilepsy fellows to undertake a mentored research project on anti-epileptic drug therapy during their fellowship training, and funds to support attendance at the AES Annual Meeting. The award does not require past experience with research or a specific percent protected time for research but instead focuses on the mentorship and training experience for the fellow. Applicants may request funding periods of six months to one year. | USD 22,000 | 1 year | American Epilepsy Society (AES) | January 18, 2024 | Not applicable | https://www.aesnet.org/research-funding/funding/early-career/the-epilepsy-study-consortium-mini-grant | |||
| 28 | Strengthening Health and Disease Modeling for Public Health Decision Making in Africa | This request for proposals (RFP) seeks proposals for innovative, high-quality modeling projects that will address specific research questions whilst: • increasing connectedness between African modeling institutes. • growing the African modeling ecosystem. • accelerating the translation of modeling outputs into meaningful policy and programmatic impact. | $3,000,000 | 5 years | Wellcome / BMGF | Oct 23 2023 | Not applicable | https://gcgh.grandchallenges.org/challenge/strengthening-health-and-disease-modeling-public-health-decision-making-africa | |||
| 29 | Postdoctoral Research Associate Training (PRAT) Program (Fi2) | The NIGMS Postdoctoral Research Associate Training (PRAT) Program’s overarching goal is to provide high quality postdoctoral research training in the basic biomedical sciences to a diverse group of postdoctoral fellows in NIH intramural research laboratories, and to prepare them for leadership positions in careers in the biomedical research workforce. Research projects proposed should fall within basic biomedical fields relevant to the NIGMS mission. In addition to the laboratory experience, the PRAT program provides a structured training environment with extensive career and professional development, mentoring, and networking opportunities planned and supported by the program. | Refer to the FOA | 3 years | National Institutes of Health (NIH) | October 03, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-191.html | |||
| 30 | Biotypes of CNS Complications in People Living with HIV (P01 Clinical Trial Not Allowed) | The goal of this Notice of Funding Opportunity (NOFO) is to understand the heterogeneity of central nervous system (CNS) outcomes in people with HIV on Anti-retroviral therapy (ART), employing quantitative assessments that are linked to psychopathology to identify distinct disease phenotypes, known as biotypes. This NOFO encourages research studies to aid in the identification/ validation of biologically quantifiable readouts in domestic and international settings. Applications responding to this NOFO are strongly encouraged to propose research strategies that are novel and have the potential to lead science beyond its current state. Multidisciplinary research teams and collaborative alliances are encouraged. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | December 11, 2023 | November 11, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-24-235.html | |||
| 31 | Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed) | The purpose of this notice of funding opportunity (NOFO) is to seek applications that examine protein interaction networks in HIV-infected microglia, and how these host-viral interactions contribute to cell type- and brain region-specific alterations in cellular signaling in the context of comorbid HIV and substance use disorder (SUD). | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | August 14, 2025 | 30 days prior to receipt date | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-014.html | |||
| 32 | Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required) | The purpose of this notice of funding opportunity (NOFO) is to support the testing of enhanced models of care that optimally integrate HIV and Hepatitis B and C, addiction, and primary care services. The National Institute on Drug Abuse (NIDA) is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV, Hepatitis (optional), and substance use disorder (SUD) in the US. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | March 19, 2025 | Not applicable | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-019.html | |||
| 33 | Addressing HIV in Highest Risk Sexual and Gender Minorities (R01 Clinical Trial Optional) | Substance use needs to be better incorporated into interventions for the engagement and retention of sexual minority persons in prevention and care with attention to emergent interventions such as long-acting PrEP. Social determinants of health associated with HIV and problematic substance use such as homelessness and criminal justice involvement also demonstrate disproportionate impact among sexual and gender minorities and need attention. Changing self-definition of sexual minority status has implications for outreach and provider stigma and needs to be better integrated into interventions. This initiative will address these gap areas and support epidemiologic, intervention, and implementation research that incorporates attention to HIV as a syndemic including comorbidities such as STIs, HCV, and psychiatric disorder. | $500,000 per year | 5 years | National Institutes of Health (NIH) | August 14, 2024 | July 14, 2024 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-001.html | |||
| 34 | Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional) | To develop and/or pilot test interventions for HIV/AIDS-associated stigma and its outcome on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on or leading to interventions to address a) innovation in measurement of HIV-associated stigma and of other intersecting stigmas due to multiple morbidities to develop better interventions, b) stigma and adolescent and/or youth health, c) effects of stigma on family members or care givers of PLWH, and on the aging PLWH, d) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission and e) coping with the complexity of added burden of stigmatization due to HIV and to one or more comorbidities/coinfections. | $400,000 | 3 years | National Institutes of Health (NIH) | December 20, 2023, December 20, 2024 | November 20, 2023; November 20, 2024 | https://grants.nih.gov/grants/guide/pa-files/PAR-23-190.html | |||
| 35 | Fc-Dependent Mechanisms of Antibody-Mediated Killing (R01 Clinical Trial Not Allowed) | The purpose of this notice of funding opportunity (NOFO) is to support basic research that will elucidate mechanisms of Fc-mediated antibody functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). Supported studies are expected to generate foundational data and tools that can be applied to the prediction of Fc-mediated killing activity by antibodies. Such data should accelerate the development of therapeutic monoclonal antibodies and the design of vaccines or vaccine-adjuvant combinations that induce antibody responses capable of killing infected host cells, particularly in cases where induction of neutralizing antibodies fails or is insufficient for clearance of infection. | $300,000 per year | 5 years | National Institutes of Health (NIH) | January 26, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-054.html | |||
| 36 | Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. | USD 600,000 per year | 5 years | National Institute of Health (NIH) | November 17, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-016.html | |||
| 37 | Minor Use Minor Species Development of Drugs (R01) | This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). | USD 250,000 per year | 3 years | National Institute of Health (NIH) | February 2, 2024 | June 12, 2023 December 15, 2023 | https://grants.nih.gov/grants/guide/pa-files/PAR-21-179.html | |||
| 38 | HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain (R01 Clinical Trial Not Allowed) | This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | November 07, 2023, March 06, 2024 | 30 days prior to the application due date. | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-070.html | |||
| 39 | Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) is soliciting Transformative Research Award applications to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies related to Down syndrome. | $6,000,000 | five years | National Institute of Health (NIH) | July 01, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-009.html?utm_medium=email&utm_source=govdelivery | |||
| 40 | Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) | The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. | $1,500,000 per year | 4 years | National Institutes of Health (NIH) | February 05, 2024, June 05, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-047.html | |||
| 41 | Tobacco Regulatory Science (R01 Clinical Trial Optional) | The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this NOFO will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this NOFO are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. | $500,000 per year | 5 years | National Institutes of Health (NIH) | May 06, 2024, October 04, 2024 | 60 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-017.html | |||
| 42 | Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) | The National Institutes of Health (NIH) is inviting applications for this Research Project Grant. The purpose of this Funding Opportunity Announcement (FOA) is to solicit R01 research projects utilizing state-of-the-art cancer biology methods and model systems to study the effects of different types of radiation used in radionuclide-based therapeutics (e.g., radiopharmaceutical therapy) on normal tissue, tumor cells, and the tumor microenvironment. | $500,000 per year | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html | |||
| 43 | Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed) | The purpose of this initiative is to promote the screening, functional validation and characterization of birth defects-associated genetic variants identified through public facing databases and individual efforts using in-silico tools, appropriate animal models, in vitro systems or multi-pronged approaches. This initiative addresses a challenging gap between identifying sequence variations of potential interest and recognizing which of those variations have functional effects on the phenotype of interest. | $499,999 per year | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, February 05, 2025 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-229.html | |||
| 44 | Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed) | This funding opportunity announcement (FOA) provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. | USD 499,000 per year | 3 years | National Institute of Health (NIH) | October 20, 2023, February 20, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-122.html | |||
| 45 | Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Research Project Grant. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. | $499,000 per year | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-206.html | |||
| 46 | Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) | The National Institutes of Health (NIH) is inviting applications for Research Project Grant. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease. The rationale is to deliver new capabilities to meet evolving requirements for technologies and methods relevant to the advance of research and delivery of care in pre-clinical, clinical and non-clinical settings, domestic or foreign, for conditions and diseases within the missions of participating institutes. This FOA specifies a partnership structure that is expected to help bridge gaps in knowledge and experience by engaging the strengths of academic, industrial, and other investigators. The partners on each application should establish an inter-disciplinary, multi-institutional research team to work in strategic alliance to implement a coherent strategy to develop and translate a solution to their chosen problem. | $499,000 per year | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-166.html | |||
| 47 | Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed) | he purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform their understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, ‘omics methods (genomics, proteomics, metabolomics, etc.), synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmental, or gene/environment interactions associated with the formation of, susceptibility to, and variability of structural birth defects in human populations. | $499,999 per year | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html | |||
| 48 | BRAIN Initiative: Targeted BRAIN Circuits Planning Projects - TargetedBCPP (R34 Clinical Trial Not Allowed) | This R34 NOFO solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - Targeted BCP R01, as described in the companion NOFO (RFA-NS-23-024). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. | $450,000 | 2 years | National Institutes of Health (NIH) | June 28, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-023.html | |||
| 49 | Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) | The purpose of this FOA is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. | $450,000 | 3 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-131.html | |||
| 50 | Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) | This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions for people who use drugs. Primary outcomes of interest include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. | $450,000 | 3 years | National Institute of Health (NIH) | January 07, 2024, May 07, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PA-21-205.html | |||
| 51 | Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for substance use and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used herein a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediation, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. | USD 450,000 | 3 years | National Institutes of Health (NIH) | March 21, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-183.html | |||
| 52 | Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required) | his Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research for people who use drugs. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons living with HIV. | $450,000 | 3 years | National Institute of Health (NIH) | January 07, 2024, May 07, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PA-21-205.html | |||
| 53 | Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for substance use and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used herein a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediation, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. | USD 450,000 | 3 years | National Institutes of Health (NIH) | March 21, 2024, August 09, 2024, March 21, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-183.html | |||
| 54 | Pediatric Immune System – Ontogeny and Development (INTEND) (R01 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to correlate immune system development patterns between two or more age groups - neonates, infants, and children and adolescents and further understand the impact of infectious diseases, microbiome and environmental factors on the ontogeny and development of the pediatric immune system, from birth, transitioning into adolescence and adulthood with the focus of impact during pregnancy and post-natal period. | $400,000 | 4 years | NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | February 05, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-248.html | |||
| 55 | Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional | This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis | $400,000 per year | 5 years | National Institutes of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-099.html | |||
| 56 | Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods. | $325,000 per year | 2 years | National Institute of Health (NIH) | October 18, 2023, February 20, 2024, June 18, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html | |||
| 57 | Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this FOA supports a Go/No-Go approach to funding high-risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated “Go/No-Go” criteria by the end of Year 2. | $350,000 per year | 4 years | National Institutes of Health (NIH) | August 02, 2024, August 01, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-169.html | |||
| 58 | NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) | The National Eye Institute (NEI) supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. | USD 300,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-128.html | |||
| 59 | Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country. | $280,000 per year | 5 years | National Institute of Health (NIH) | August 22, 2024 | 30 days before receipt date. | https://grants.nih.gov/grants/guide/pa-files/PAR-22-151.html | |||
| 60 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | The National Institutes of Health (NIH) is inviting applications for this Exploratory/Developmental Research Grant. This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html | |||
| 61 | Biology of Bladder Cancer (R21 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) seeks applications investigating the biology and underlying mechanisms of bladder cancer. | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-219.html | |||
| 62 | Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed) | This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward developing next-generation human cell-derived microphysiological systems (MPS) and related assays that replicate complex nervous system architectures and physiology with improved fidelity over current capabilities. Supported projects will be expected to enable future studies of complex nervous system development, function and aging in healthy and disease states. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-047.html | |||
| 63 | Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed) | The National Institutes of Health (NIH) is inviting applications for this Exploratory/Developmental Research Grant. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease and its related dementias and which need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA. | USD 275,000 | 2 years | National Institutes of Health (NIH) | November 13, 2023, March 11, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html | |||
| 64 | Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional) | The purpose of this funding opportunity announcement (FOA) is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics. | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-131.html | |||
| 65 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. | $275,000 | 2 years | National Institutes of Health (NIH) | October 10, 2023, February 13, 2024, June 12, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html | |||
| 66 | Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) solicits applications for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. | $275,000 | 2 years | National Institute of Health (NIH) | November 01, 2023 | October 1, 2023 | https://grants.nih.gov/grants/guide/pa-files/PAR-21-264.html | |||
| 67 | Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. | USD 275,000 | 2 years. | National Institute of Health (NIH) | October 16, 2023 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-288.html | |||
| 68 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) | The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementia (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. PAR-20-157 uses the R01 grant mechanism, while PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. | $275,000 | 2 years | National Institutes of Health (NIH) | October 05, 2023, February 05, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-208.html | |||
| 69 | Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for this Exploratory/Developmental Research Grant. Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) encourages the submission of exploratory/developmental research grant (R21) applications that focus on different aspects of cancer control by modifying behavior, screening, and understanding etiologic factors contributing to the development of cancer, and developing ways to control cancer. | USD 275,000 | 2 years | National Institute of Health (NIH) | October 09, 2023, June 07, 2024, October 08, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-341.html | |||
| 70 | Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional) | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024, June 16, 2024 | 30 days prior to the due date. | https://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html | |||
| 71 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional | This Funding Opportunity Announcement (FOA) supports preclinical and early phase clinical research, as well as correlative studies, directly related to advancements in cancer treatment, diagnosis, prevention, symptom management, or reduction of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. | USD 275,000 | 2 years | National Institute of Health (NIH) | October 10, 2023, February 13, 2024,and June 12, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-216.html | |||
| 72 | NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project's specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project's originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data | USD 275,000 | 2 years | National Institute of Health (NIH) | October 16, 2023, February 16, 2024, June 16, 2024, October 16, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-141.html | |||
| 73 | NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) | This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. | $250,000 per year | 4 years | National Institute of Health (NIH) | February 05, 2024 , and June 05, 2024. | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-034.html | |||
| 74 | Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed) | The goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. This FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as pharmacokinetic/pharmacodynamic (PK/PD) markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline in which treatment candidates and therapeutic targets can be evaluated for their ability to impact neurobiological mechanisms of potential clinical relevance to mental illnesses. | USD 250,000 | 5 years | National Institute of Health (NIH) | February 05, 2024, and June 05, 2024. | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-170.html | |||
| 75 | Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R01-Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications proposing the analysis of this public use dataset to increase knowledge of adolescent health and development. | USD 250,000 | 5 years. | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-137.html | |||
| 76 | Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies", or other biospecimens as described in this FOA. | USD 250,000 per year | 5 years. | National Institute of Health (NIH) | January 11, 2024, June 07, 2024, September 13, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-049.html | |||
| 77 | International Bioethics Research Training Program (D43 Clinical Trial Optional) | The overall goal of this initiative is to support the mentored training of a sustainable critical mass of bioethics scholars in low and middle-income country (LMIC) research-intensive institutions with the capabilities to conduct original empirical or conceptual ethics research that addresses challenging issues in health research and research policy in these countries as well as provides research ethics leadership to their institutions, governments, and international research organizations. | USD 230,000 per year | 5 years. | National Institute of Health (NIH) | June 06, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-116.html | |||
| 78 | Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional) (PAR-22-104) | The Chronic, Noncommunicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award program supports collaborative research training between institutions in the U.S. and low-and middle-income countries (LMICs), defined by the World Bank classification system . This institutional research training program aims to sustainably strengthen the research capacity of the LMIC institutions, and to train in-country experts to conduct research on chronic, noncommunicable diseases and disorders, with the ultimate goal of implementing evidence-based interventions relevant to their countries. | $230,000 per year | 5 years | National Institutes of Health (NIH) | July 15, 2024 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-104.html | |||
| 79 | International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed) | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support "the ethics of" educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. (The overarching goal of this R25 program is to support educational activities that foster a better understanding of "the ethics of" biomedical, behavioral and clinical research and its implications.) | USD 230,000 per year | 5 years | National Institute of Health (NIH) | June 06, 2024 | 07/05/2022, May 6, 2023, May 6, 2024 | https://grants.nih.gov/grants/guide/pa-files/PAR-22-118.html | |||
| 80 | NCMRR Early Career Research Award (R03 Clinical Trial Optional) | The NCMRR ECR Award R03 grant mechanism supports various types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award R03 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application. | $200,000 | 2 years. | National Institute of Health (NIH) | March 28, 2024, March 28, 2025 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-029.html | |||
| 81 | Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) | This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed. | $200,000 | 2 years | National Institute of Health (NIH) | October 16, 2023, February 16, 2024, June 16, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-075.html | |||
| 82 | Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to provide support for new investigators from diverse backgrounds, including from groups nationally underrepresented in biomedical research, to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and participating Institutes and Centers. | $125,000 per year | 3 years. | National Institute of Health (NIH) | October 16, 2023 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-313.html | |||
| 83 | Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, piloting innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system-related function and disorders throughout life, relevant to LMICs. | $125,000 per year | 2 years. | National Institute of Health (NIH) | November 15, 2023 | 30 days before receipt date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-319.html | |||
| 84 | Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional) | This Small Research Grant (R03) program will support meritorious projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this NOFO will support projects covering a wide range of topics related to AD/ADRD. The overall goal of this NOFO is (i) to encourage the next generation of researchers to pursue research and academic careers in AD/ADRD research; and (ii) to stimulate established researchers who have not had a major award in AD/ADRD research to perform pilot studies to develop new, innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from diverse backgrounds, including those from underrepresented groups are always encouraged to apply for NIH support. Investigators who have not successfully competed for an award under this or prior versions of this announcement are specifically encouraged to apply. | $100,000 per year | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024, June 16, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-179.html | |||
| 85 | NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) | This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. | USD 100,000 | 2 years. | National Institutes of Health (NIH) | October 20, 2023 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-20-052.html | |||
| 86 | Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed) | The overall goal of the Fogarty HIV Research Training (HIVRT) Program is to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) by enhancing the functional resources required to conduct HIV research on the evolving HIV epidemic in their countries. | $94,000 per year | 3 years. | National Institute of Health (NIH) | August 22, 2024 | 30 days before application due date. | https://grants.nih.gov/grants/guide/pa-files/PAR-22-153.html | |||
| 87 | Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation of research methods and measures are encouraged. Applications that focus on the re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged | USD 50,000 per year | 2 years | National Institutes of Health (NIH) | October 16, 2023, February 16, 2024, June 16, 2024, October 16, 2024, February 16, 2025 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-160.html | |||
| 88 | Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. | $50,000 | 2 years | National Institute of Health (NIH) | October 18, 2023, October 16, 2023 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-324.html | |||
| 89 | Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed) | The Fogarty HIV Research Training (HIVRT) Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMICs). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to prepare to participate in the Fogarty HIV Research Training Program. | $ 28,000 per year | 2 years | National Institute of Health (NIH) | August 22, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-152.html | |||
| 90 | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-329.html | |||
| 91 | Biology of Bladder Cancer (R01 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024 , and June 05, 2024. | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-218.html | |||
| 92 | NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) | The National Institutes of Health (NIH) is inviting applications for Exploratory/Developmental Phased Award Cooperative Agreement. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | October 10, 2023, February 09, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-237.html | |||
| 93 | Laboratories to Optimize Digital Health (R01 Clinical Trial Required) | NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. | Application budgets are not limited | 4 years. | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-154.html | |||
| 94 | Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (R01 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Research Project Grant. A growing body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings indicate that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for the treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This Funding Opportunity Announcement (FOA) supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-175.html | |||
| 95 | NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Research Project – Cooperative Agreements. This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests. Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. Applicants do not need to be part of the existing NeuroNEXT infrastructure. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-223.html | |||
| 96 | Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies on host cell death pathways and their effect on immune responses to Mycobacterium tuberculosis (Mtb) and Mtb/HIV co-infection to identify immune targets for development of host-directed therapies. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | December 07, 2023, December 07, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-223.html | |||
| 97 | Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | This Funding Opportunity Announcement supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (DCC). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. | Application budgets are not limited | Refer to FOA | National Institute of Health (NIH) | October 11, 2023, February 13, 2024, June 11, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html | |||
| 98 | NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory Phase 1 and Phase 2 clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). These trials must address questions within the mission and research interests of the NINDS. They may include studies of drugs and biologics, feasibility or preliminary efficacy studies of devices, and early studies of surgical, behavioral or rehabilitation therapies. All Phase 1 exploratory trials must contribute to the justification for and provide some of the data required to inform a future Phase 2 trial that may also be performed as part of the current grant application, should the results of the Phase 1 studies be encouraging. This FOA uses the UG3/UH3 mechanism. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | October 10, 2023, February 08, 2024, June 10, 2024 | 30 days prior to application due date. | https://grants.nih.gov/grants/guide/pa-files/PAR-22-142.html | |||
| 99 | Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required) | This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-129.html | |||
| 100 | Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) | The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-137.html | |||
| 101 | Co-infection and Cancer (R01 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents – either concurrently or sequentially – and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024 | 30 days prior to the Application Due Date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-055.html | |||
| 102 | Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional) | This FOA invites researchers to submit prospective clinical projects that address critical needs for clinical trial readiness in FNDs. Projects appropriate for this FOA include the validation of biomarkers, endpoints and clinical outcome assessments (COA) that are fit-for-purpose and have a defined context of use for clinical trials. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-053.html | |||
| 103 | Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional) | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html | |||
| 104 | Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications to support research in established cancer epidemiology cohort studies, defined as studies that have achieved their initial planned recruitment goal. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 28, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html | |||
| 105 | Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) | Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to “Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts” PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 28, 2024, July 29, 2024, and February 28, 2025 | Optional | https://grants.nih.gov/grants/guide/pa-files/PAR-22-161.html | |||
| 106 | Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) | This FOA seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (e.g., psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-130.html | |||
| 107 | Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) | The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms. | Application budgets are not limited | 3 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-134.html | |||
| 108 | Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) | The purpose of this FOA is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-132.html | |||
| 109 | Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) | The purpose of this FOA is to encourage pilot research developing and testing innovative psychosocial intervention approaches in which the target and/or intervention strategy is novel. Consistent with NIMH’s experimental therapeutics approach, this FOA is intended to speed the translation of emergent research on mechanisms and processes underlying mental disorders into promising novel psychosocial preventative or therapeutic interventions. Targets may include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | October 17, 2023, February 15, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-135.html | |||
| 110 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024 , June 05, 2024, October 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-085.html | |||
| 111 | Clinical Studies of Mental Illness (Collaborative R01 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, that primarily focus on mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology). | Application budgets are not limited | 5 years | National Institute of Health (NIH) | October 05, 2023, February 05, 2024, June 05, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-050.html | |||
| 112 | NEI Vision Research Epidemiology Grant (UG1 Clinical Trial Not Allowed) | The National Eye Institute (NEI) supports investigator-initiated, complex, multi-center and other high resource risk epidemiologic studies under the cooperative agreement mechanism, UG1 activity code. Specifically, the purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative ocular epidemiology research. | Budgets are not limited | 5 years | National Institute of Health (NIH) | September 25, 2023, January 25, 2024, May 25, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-204.html | |||
| 113 | Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required) | This funding opportunity announcement (FOA) invites research projects that seek to explain the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in human health, illness, recovery, and overall wellbeing. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | June 21, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-352.html | |||
| 114 | Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed) | This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | June 21, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-350.html | |||
| 115 | The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional) | This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | December 15, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-348.html | |||
| 116 | BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional) | The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative Funding Opportunity Announcement is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | June 07, 2024. | 30 days prior to application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-115.html | |||
| 117 | Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) | This Funding Opportunity Announcement (FOA) supports applications to develop and implement investigator-initiated single-site clinical trials including efficacy, comparative effectiveness, pragmatic, and/or implementation research clinical trials. Trials using innovative designs such as platform trials, adaptive, and Bayesian designs are encouraged. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. This FOA will utilize a bi-phasic, milestone-driven mechanism of the award. The objective of the application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. The application should also describe its approaches to increasing community engagement, reducing health inequities and disparities, and include a Plan for Increasing Diverse Perspectives (PDEP). | Application budgets are not limited | 5 years | National Institute of Health (NIH) | October 11, 2024, February 11, 2025, and June 11, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-189.html | |||
| 118 | Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional) | The goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The Funding Opportunity Announcement (FOA) will support efforts to optimize and evaluate pharmacodynamic (PD) measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in other species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data may also reveal assay measures where performance is dissimilar between preclinical animal species and humans, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. | Application budgets are not limited | 3 years | National Institute of Health (NIH) | October 21, 2023, February 21, 2024, and June 21, 2024 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-169.html | |||
| 119 | Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional) | The purpose of this Notice of Funding Opportunity (NOFO) is to support applications for epidemiological and observational research projects on the long-term cardiopulmonary sequelae following treatment for tuberculosis (TB). Investigators should propose additional testing and data collection in existing cohorts of adult and/or pediatric TB participants to better characterize and understand adverse outcomes and morbidity associated with TB disease post treatment in individuals with and without HIV infection. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | January 07, 2024, May 07, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-148.html | |||
| 120 | Biological Testing Facility (X01 Clinical Trial Not Allowed) | The purpose of this notice of funding opportunity (NOFO) is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program. This NOFO aims to position innovative and validated methods for future clinical development. Applicants do not need to have current NIH funding to apply, but priority may be given to programs receiving NIH support at the time of application submission. | There is no budget associated with X01 Resource Access Awards | one year | National Institutes of Health (NIH) | January 2, 2024; May 2, 2024; January 2, 2025; May 2, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-192.html | |||
| 121 | BRAIN Initiative: Optimization of Instrumentation and Device Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | This Funding opportunity announcement seeks applications to optimize instrumentation and device technologies for recording and modulation of neural cells and circuits, to address major challenges, and to enable a transformative understanding of dynamic signaling in the central nervous system. It is expected that the proposed technologies and approaches have previously demonstrated their transformative potential through initial proof-of-concept testing, and are ready for accelerated refinement through iterative engineering and end-user feedback, appropriate for a path toward sustainable dissemination and user-friendly incorporation into routine neuroscience research. Applications may propose the development of instrumentation hardware and/or devices and associated software. Approaches may utilize any modality such as optical, electrical, magnetic, or acoustic recording/manipulation, to target neuronal electrical signals or other forms of neural activity, including intracellular signaling and engagement of non-neuronal cells in circuit function. | Application budgets are not limited | 4 years | National Institutes of Health (NIH) | January 19, 2024, October 01, 2024, June 02, 2025, | 60 days prior to the receipt date. | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-005.html | |||
| 122 | BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed) | National Institutes of Health (NIH) is inviting applications for Research Project Grant. This FOA solicits applications for research projects that seek to understand how circuit activity gives rise to mental experience and behavior using innovative, methodologically-integrated approaches. The goal is to support adventurous projects that can realize a potentially transformative outcome within 5 years. Applications are expected to address circuit function in the context of specific behaviors or neural systems, such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication, or homeostasis. Projects should link theory, data analysis, and/or computational approaches to experimental design and should produce predictive models (conceptual or quantitative). Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Diverse species or experimental systems and a cross-species/comparative approach are welcome and should be chosen based on their power to address the specific question at hand and to reveal generalizable and fundamental neuroscience principles. | Application budgets need to reflect the actual needs | 5 years | National Institutes of Health (NIH) | June 28, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-23-024.html | |||
| 123 | Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional) | The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research. Specifically, test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological treatments. Research of interest includes but is not limited to Stage II and Stage III efficacy research, including: (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies to boost effects and increase implementability and sustainability; (4) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (5) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (6) interventions to treat substance misuse and chronic pain. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | March 21, 2024, August 09, 2024, March 21, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-22-182.html | |||
| 124 | Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance-using behaviors (defined as alcohol, tobacco, prescription and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance-using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | November 15, 2023, March 04, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-037.html | |||
| 125 | Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional) | The purpose of this notice of funding opportunity (NOFO) is to support translational and clinical research to (1) advance precision medicine in pregnant persons, lactating persons, and children through the development of novel tools, models, and other technologies that could have a direct clinical or health impact; (2) enhance the understanding of the underlying mechanisms of drug action, including the role of pediatric ontogeny and the dynamic physiological changes that occur during pregnancy and lactation; and (3) discover and develop novel therapeutics or enhance the usage of existing drugs or drug repurposing for safer and more effective medications in pregnant and lactating persons, neonates, and children. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-130.html | |||
| 126 | Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional) | The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS. Findings may also provide insight into novel therapeutic targets that can be advanced into interventions to treat and prevent the development of NPS in AD and/or ADRD. This FOA uses the R01 mechanism, while the companion announcement PAR-20-159 uses the R21 mechanism. High-risk/high-payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-207.html | |||
| 127 | Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA. | $275,000 | 2 years | National Institutes of Health (NIH) | November 15, 2023, March 04, 2024 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-038.html | |||
| 128 | Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing new tests, animal models, techniques, etc. to advance research on Alzheimer's disease (AD) and its related dementias (ADRD) that need additional preliminary data with broader dissemination to establish them for more general use in this research field. The priority topics will be announced through a series of Notices published subsequent to this FOA. | $275,000 | 2 years | National Institutes of Health (NIH) | November 13, 2023, March 11, 2024, July 09, 2024, November 12, 2024 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html | |||
| 129 | Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Exploratory/Developmental Research Grant. The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. | $275,000 | 2 years | National Institutes of Health (NIH) | March 8, 2024 | 30 days prior to the application due date. | https://grants.nih.gov/grants/guide/pa-files/PAR-21-208.html | |||
| 130 | Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | Avenir means future in French, and this Avenir Award Program looks toward the future by supporting early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and addiction. The purpose of this award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. | $300,000 per year | 5 years | National Institutes of Health (NIH) | August 09, 2024, August 07, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-007.html | |||
| 131 | Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Exploratory/Developmental Phased Award Cooperative Agreement. The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 09, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-163.html | |||
| 132 | BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) | The purpose of the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that clearly complements their predoctoral research. Formal training in analytical tools appropriate for the proposed research is expected to be an integral component of the research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 12 months of postdoctoral training. | Application budgets are not limited | 3 years | National Institutes of Health (NIH) | April 09, 2024, December 10, 2024, August 11, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-110.html | |||
| 133 | Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed) | This Funding Opportunity Announcement (FOA) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this FOA, the term “complex” can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to “model” disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html | |||
| 134 | International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply. Eligibility status of applicant organizations will be determined by the World Bank Classification list at the time of application submission. | $125,000 per year | 5 years | National Institutes of Health (NIH) | August 02, 2024, August 01, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-023.html | |||
| 135 | Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) | This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. | USD 275,000 | 2 years | National Institutes of Health (NIH) | December 01, 2023, February 01, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-004.html | |||
| 136 | Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for Method to Extend Research in Time (MERIT) Award. The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs) who qualify for conversion based on receiving a percentile within the NCI payline for established investigators on their R01 applications. By providing longer term support to ESIs who qualify, the NCI intends to offer flexibility and opportunity for creativity and innovation and additional time to successfully launch their careers and to become more established before having to submit renewal applications (NOT-CA-18-037). The objective of the NCI's ESI MERIT Award is to allow eligible investigators the opportunity to obtain up to 7 years of support in two segments: The initial approved duration of the award; and A second phase, providing an additional two years of support. This funding opportunity announcement is specifically for currently funded NCI ESI MERIT recipients to request the second phase of the initial award. | Not specified | 2 years | National Institutes of Health (NIH) | July 1 2024, November 1 2023, March 1 2024. | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-138.html | |||
| 137 | Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to accelerate research to better understand the emergence, trajectory, and outcome of schizophrenia and related psychotic disorders in mid-to-late life. For the purposes of this FOA, schizophrenia and related psychotic disorders include nonaffective psychotic disorders (e.g., schizophrenia spectrum disorders, delusional and other nonorganic psychotic disorders) but also bipolar disorder with psychosis. Since on average, persons with schizophrenia and related psychotic disorders have a shorter lifespan, the mid-to late-life life period is defined as 35 years old and above. Research that identifies mechanisms underlying the risk, emergence, and outcome of schizophrenia and related psychotic disorders during mid to late life is of special interest. Mechanisms include, but are not limited to biological, behavioral, psychosocial, and environmental. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html | |||
| 138 | New Global Program to Help Customers Develop Cloud Solutions to Advance Health Equity | Amazon Web Services will support organizations that are building culturally responsive, cloud-based solutions that advance health equity and improve health outcomes among underserved or underrepresented communities around the world. These include solutions that meaningfully engage underserved and underrepresented populations and increase access to health and social services, reduce the impact of social determinants of health, and leverage data to promote equitable and inclusive systems of care. | $40M | Not specified | Amazon | November 15, 2023. | Not applicable | https://aws.amazon.com/government-education/nonprofits/global-social-impact/health-equity/ | |||
| 139 | IBD Plexus: Academic Request for Proposals | IBD Plexus was founded by the Foundation to advance science, accelerate progress towards precision medicine, and improve the care of patients with IBD. This first-of-its-kind, national-scale, cloud-based platform integrates clinical, patient-reported, genetic, and other molecular data from diverse research study cohorts, real-world clinical care settings, and patients’ experiences. This RFP was made possible with the support of The Leona M. and Harry B. Helmsley Charitable Trust and Takeda Pharmaceutical Company Limited. The Crohn’s & Colitis Foundation is excited to release an international request for proposals (RFP) for academic researchers to gain access to IBD patients’ biosamples and research-ready datasets housed within IBD Plexus®. The Foundation seeks research proposals that would utilize IBD Plexus biosamples and/or data to facilitate efforts in 4 main areas: 1) identification and/or validation of diagnostics/biomarkers, 2) therapeutic development and optimization 3) disease management 4) disease prevention | Not specified | Not specified | Crohn's & Colitis Foundation | Dec-23 | Not applicable | https://www.crohnscolitisfoundation.org/research/grants-fellowships/ibd-plexus | |||
| 140 | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) | Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/ glucose?dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. Investigators wishing to study incretin mimetics other than GLP-1 RAs or GLP-1/GIP-1 RAs, such as dipeptidyl peptidase (DPP)-4 inhibitors, must justify why the agent(s) they propose to study are more effective and/or have a more favorable side effect profile than GLP-1 or GLP-1/GIP-1 RAs. Route of agent administration (oral vs. other) is, by itself, not an adequate justification | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html | |||
| 141 | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) | Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for investigator-initiated studies addressing mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP)-1 receptor agonists (RAs), impact cancer risk. The focus on these agents is due to their reported effects on thyroid, prostate and other cancer risks, and the generally more favorable efficacy and side effect profile compared to other classes of incretin mimetics. In addition, this NOFO seeks to draw in talented scientists to the cancer biology field who may study incretin mimetic effects on diseases other than cancer. | $275,000 | 2 years | National Institute of Health (NIH) | February 16, 2024, June 16, 2024, October 16, 2024, February 16, 2025, June 16, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-280.html | |||
| 142 | Seamless Early-Stage Clinical Drug Development for Novel therapeutic Agents for the Spectrum of Alzheimers Disease and AD-related Dementias (UG3/UH3 Clinical Trial Required) | The purpose of this notice of funding opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and AD-related dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum, from pre-symptomatic to more severe stages of disease. This NOFO uses a phased award activity code. Applications must include prespecified, go/no-go safety and tolerability milestones that must be met to advance from phase 1 to latter stages of clinical development. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 21, 2024, June 20, 2024, October 21, 2024, February 21, 2025,June 23, 2025 | January 19, 2024 | https://grants.nih.gov/grants/guide/pa-files/PAR-23-274.html | |||
| 143 | Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. The NCI, through this NOFO encourages submission of projects devoted to demonstrating that mammalian models, including organoids, tumoroids and cell models, used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patient benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that use mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this NOFO could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally. | $499,000 per year | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html | |||
| 144 | Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) | The purpose of this notice of funding opportunity (NOFO) is to accelerate the development of devices to treat Substance Use Disorders (SUDs). The continuing advances in technologies offer unprecedented opportunities to develop neuromodulatory or neurophysiological devices that are safe and effective SUD treatments. The objective is to move devices to their next step in the FDA approval process, with the ultimate goal of generating new, FDA-approved device-based treatments for SUDs. Applications may focus on the pre-clinical and/or clinical development and testing of new devices or existing devices approved for other indications. Applications may evaluate the mechanism of action of a device. The UG3/UH3 Cooperative Agreement involves two phases. The UG3 phase, for up to two years, is designed to support a project with specific milestones to be accomplished by the end of the period. The UH3 phase is to provide funding for up to three additional years following successful completion of the UG3. | Application budgets are limited | 3 years | National Institute of Health (NIH) | December 18, 2023, August 13, 2024, December 18, 2024, August 13, 2025, December 18, 2025, August 13, 2026 | 30 days prior to the application due. | https://grants.nih.gov/grants/guide/pa-files/PAR-23-253.html | |||
| 145 | Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)(U01 Clinical Trial Optional) | This notice of funding opportunity (NOFO) invites applications to accelerate the establishment of effective and reliable biomarkers of Alzheimer’s disease (AD) and AD-related dementias (ADRD) for use in therapy/medical product discovery and development, clinical trials, and/or clinical practice. Specifically, this NOFO will support analytical and/or clinical validation of a biomarker, composite biomarker, or biomarker signature, with rigor comparable to the expectations described in the Food and Drug Administration (FDA's) Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways | Application budgets are not limited | 5 years | National Institute of Health (NIH) | November 03, 2023, February 05, 2024, October 05, 2024, February 05, 2025, October 05, 2025, February 05, 2026 | October 3, 2023 | https://grants.nih.gov/grants/guide/pa-files/PAR-23-258.html | |||
| 146 | Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional) | This Notice of Funding Opportunity (NOFO) aims to support research on interdisciplinary population approaches to increasing awareness of the relationship between alcohol and cancer risk, understanding and changing social norms related to alcohol consumption, developing and/or evaluating alcohol policy approaches, and the development, testing, and implementation of population-level interventions to reduce alcohol-related cancer risk. Applications that address multiple levels of consumption, such as moderate and heavy drinking, are of particular interest, as well as those focusing on alcohol use disorder (AUD) from the perspective of cancer prevention and control. Proposals addressing understudied areas are encouraged, as is attention to underrepresented minority (URM) populations experiencing cancer and alcohol-related disparities such as American Indian, Alaskan Native, and sexual and gender minority populations | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025, June 05, 2025, October 05, 2025 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-244.html | |||
| 147 | Planning for Product Development Strategy (R34 Clinical Trial Not Allowed) | The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of a comprehensive and well-defined product development strategy for next-generation treatments for HIV and HIV-associated comorbidities, coinfections, and complications and preventive strategies for HIV, as well as facilitate the translation of research findings into drug products that enable submission of an Investigational New Drug (IND) application to the FDA. This NOFO will support multidisciplinary planning activities to develop a well-defined product development strategy that enables an IND submission. The IND-directed product development strategy will comprise the required components in concordance with FDA guidance, such as product indication, route of administration and dosing, CMC strategy, pharmacology and toxicology program strategies, and clinical protocol design. Finalized clinical protocols are not expected at the conclusion of the project period. | $225,000 | 1 year | National Institute of Health (NIH) | March 13, 2024, December 04, 2024, March 13, 2025, December 04, 2025, March 13, 2026, December 04, 2026 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html | |||
| 148 | NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed | The Adolescent Brain Cognitive Development(ABCD) Study is the largest longitudinal study of brain development and child health in the U.S., collecting data from more than 11,000 children across the country beginning when they were 9-10 years old and continuing for a decade. In addition to behavioral assessments, youth undergo neuroimaging and provide biospecimens, including oral fluids for hormone analysis, urine and hair for substance use and exposure, deciduous teeth for environmental exposures, and blood for genetic analysis and metabolic and hematologic assays. Interested applicants are strongly encouraged to explore available biospecimens and complete a Letter of Intent in the form of a Biospecimen Availability Inquiry via the NBDC portal at least 4 weeks prior to the submission deadline to determine whether there is a sufficient quantity of samples required for the proposed study and to determine whether the proposed use of samples is consistent with the limitations of the participant's informed consents. | Not Applicable | 3 years | National Institute of Health (NIH) | February 06, 2024, May 06, 2024, October 04, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-229.html | |||
| 149 | HEAL Initiative: Understanding Individual Differences in Human Pain Conditions (R01 - Clinical Trial Optional) | This notice of funding opportunity (NOFO) seeks to support research aimed at a holistic understanding of inter-individual or between-person differences in human pain conditions, focusing on ‘Whole Person Health’ and enhancing pain treatment and management strategies towards personalized pain medicine. The goal of this NOFO is to support studies that focus on the collection of clinical and/or preclinical data to enable evidence-based modeling and understanding of inter-individual differences and/or heterogeneity of pain occurring with the use of pain therapy/management, or with conditions such as a second pain condition, a comorbid health condition, a comorbid mental health condition, or conditions of use/misuse of opioids, alcohol or other substances. Applicants are encouraged to develop and implement novel, multidisciplinary research approaches, and include investigators with complementary expertise to fulfill the project and program goals. Input from patients and caregivers on the goals of the project is highly encouraged. Rigorous data-driven and evidence-based research approaches supported under this NOFO are expected to provide a better understanding of biological and/or biopsychosocial underpinnings of inter-individual differences, heterogeneity, and stratification of persons with lived pain experience, which would accelerate the development of evidence-based solutions toward precision pain medicine. | $650,000 per year | 5 years | National Institute of Health (NIH) | November 07, 2023, February 06, 2024, June 06, 2024, October 08, 2024 | Not Applicable. | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-021.html | |||
| 150 | Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required) | This Notice of Funding Opportunity (NOFO) will solicit mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. Expectancies are defined in this context as beliefs about future outcomes, including one’s response to cancer or cancer treatment. Expectancies can be evoked by social, psychological, environmental, and systemic factors. Expectancy effects are the cognitive, behavioral, and biological outcomes caused by expectancies. Expectancy effects can be generated by expectancies held by patients, clinicians, family members, caregivers, and/or dyadic/social networks. The program is particularly interested in applications that enroll individuals and groups from populations historically underrepresented or excluded from biomedical and behavioral research. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025, June 05, 2025 | Not Applicable. | https://grants.nih.gov/grants/guide/pa-files/PAR-23-273.html | |||
| 151 | Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization. | Application budgets are not limited | 3 years | National Institute of Health (NIH) | October 05, 2023 , February 05, 2024, June 05, 2024 , October 05, 2024 , February 05, 2025, June 05, 2025, October 05, 2025, February 05, 2026 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-264.html | |||
| 152 | Alcohol Health Services Research (R01 Clinical Trial Optional) | The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. | $500,000 | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025, June 05, 2025 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-251.html | |||
| 153 | Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required) | The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This NOFO will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. | $500,000 | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025, June 05, 2025 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-250.html | |||
| 154 | Alcohol Health Services Research (R34 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for this Planning Grant. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations. | $450,000 | 3 years | National Institute of Health (NIH) | October 16, 2023, February 16, 2024, June 16, 2024, October 16, 2024, February 16, 2025, June 16, 2025 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-252.html | |||
| 155 | Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for this Research project Grant. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging, data science and/or spectroscopic technologies into methods or tools that address contemporary problems in understanding the fundamental biology, potential risk of development, diagnosis, treatment, and/or disease status for cancer or other disease. A distinguishing feature of each application to this FOA will be formation of an academic-industrial partnership: a strategic alliance of academic and industrial investigators who work together as partners to identify and translate a technological solution for mitigation of a cancer (or other disease-related) problem. In this sense, the FOA acts more as funding mechanism for driving translational research in imaging more than for a specific scientific or clinical research area. These partnerships are expected to solidify pre-existing collaborations or new ones that would drive the field of imaging, as a whole, further than if they had not been formed. | $500,000 per year | 5 years | National Institute of Health (NIH) | February 05, 2024, June 05, 2024 , October 05, 2024 , February 05, 2025, October 05, 2025, February 05, 2026 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-259.html | |||
| 156 | Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) | This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 4-6 months. | $275,000 | 2 years | National Institute of Health (NIH) | December 01, 2023, February 01, 2024, April 01, 2024 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-004.html | |||
| 157 | Personal Health Informatics for Delivering Actionable Insights to Individuals (R01 Clinical Trial Optional) | The purpose of this Notice of Funding Opportunity (NOFO) is to advance the development of novel informatics and data science approaches that can help individuals understand and improve their health through actionable insights. The NLM and participating institutes listed in this NOFO seek applications that further the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation. Applications seeking to advance the understanding of how informatics tools, systems, and platforms can best present the results, interpretation, and limitations of personalized assessments for the benefit of individuals are encouraged. Applications should include end-user engaged approaches and real-world evaluation to inform the design of generalizable, reusable, and scalable personal health informatics tools, systems, and platforms for the benefit of individuals in understanding and improving their health. | $250,000 per year | 4 years | National Institute of Health (NIH) | October 05, 2023 , February 05, 2024, June 05, 2024 , October 05, 2024 , February 05, 2025, June 05 2025, October 05, 2025 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-245.html | |||
| 158 | Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed) | This NOFO seeks applications for the development of informatics tools to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). Emphasis for this RFA will be on development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics. These tools will use pangenome datasets and build on systems developed by the Human Pangenome Coordinating Center (see below), which will support general computational infrastructure for pangenome use. This informatics tools RFA will fund one component of an overall HGRP, which will also include two other components: High Quality Reference Genomes (herein called “Genomes Center”), and a Human Pangenome Coordinating Center (Herein called “Coordinating Center”). (See Companion Funding Opportunities). Awardees under all three RFAs will work collaboratively within a consortium towards production and community adoption of the human pangenome reference. | $400,000 per year | 3 years | National Institutes of Health (NIH) | November 01, 2023; March 03, 2025 | October 01, 2023; February 3, 2025 | https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-026.html | |||
| 159 | Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) | The goal of this notice of funding opportunity (NOFO) is to support applications for novel theory and methods development that enable a better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | February 05, 2024, June 05, 2024, October 05, 2024, February 05, 2025 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-302.html | |||
| 160 | Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed) | The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences. | $275,000 | 2 years | National Institutes of Health (NIH) | February 16, 2024, June 16, 2024, October 16, 2024, February 16, 2025, June 16, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-301.html | |||
| 161 | Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. | $300,000 per year | 5 years | National Institutes of Health (NIH) | January 25, 2024, May 25, 2024, September 25, 2024, January 25, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-276.html | |||
| 162 | Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. | $300,000 per year | 5 years | National Institutes of Health (NIH) | January 25, 2024, May 25, 2024, September 25, 2024, January 25, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-277.html | |||
| 163 | Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. | $150,000 per year | 2 years | National Institutes of Health (NIH) | January 25, 2024, May 25, 2024, September 25, 2024, January 25, 2025 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-278.html | |||
| 164 | Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional) | The NIMH invites applications for Research Project Grants (R34) that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. For the purposes of this FOA, “intervention” is defined to include behavioral, social, or structural approaches, as well as combination biomedical and behavioral, social, or structural approaches that improve HIV prevention or treatment outcomes. | $450,000 | 3 years | National Institutes of Health (NIH) | January 09, 2024, May 09, 2024, September 10, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-060.html | |||
| 165 | HIV Prevention and Alcohol (R34 Clinical Trials Optional) | The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research. | $450,000 | 3 years | National Institutes of Health (NIH) | January 07, 2024, May 07, 2024, September 07, 2024, January 07, 2025 | 30 days before application due date. | https://grants.nih.gov/grants/guide/pa-files/PAS-23-172.html | |||
| 166 | Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional) | Avenir means future in French. Accordingly, the Avenir Award Program for research on Substance Use Disorders (SUD) and HIV looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies at the intersection of HIV and substance use. Applications responding to this Funding Opportunity Announcement (FOA) must clearly describe the nexus of HIV and substance use and propose research that aligns with NIH HIV/AIDS Research Priorities NOT-OD-20-018. This FOA aims to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV. Some examples of research areas of interest to NIDA are reducing HIV incidence, optimizing therapies for HIV and SUD, minimizing the the impact of comorbidities, and achieving long-term suppression of HIV in the absence of antiretroviral (ARV) therapy. | $1,500,000 | 4 years | National Institutes of Health (NIH) | August 15, 2024, August 15, 2025 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-23-125.html | |||
| 167 | Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) | This FOA solicits innovative research to optimize HIV prevention and care which is aligned with NIMH Division of AIDS Research (DAR) priorities. Applications may include formative basic behavioral and social science to better understand a step or steps in the HIV prevention or care continuum, and/or the initial development and pilot testing of innovative intervention approaches, and intervention efficacy or effectiveness trials. Applicants are encouraged to read current Notices of Special Interests (NOSIs) from NIMH DAR for further information about the Divisions research priorities. | Application budgets are not limited | 5 years | National Institutes of Health (NIH) | January 09, 2024, May 09, 2024, September 10, 2024 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-23-062.html | |||
| 168 | Grant Funding-Fanconi Anemia Research Fund | The Fanconi Anemia Research Fund (FARF) seeks to fund interdisciplinary and translational research efforts that will lead to rapid discovery and development of therapies or strategies that treat, control, or cure Fanconi anemia (FA). | USD 250,000 | 1-2 years | Fanconi Anemia Research Fund (FARF) | No Deadline | Not Applicable | https://www.fanconi.org/explore/apply-for-grant-funding | |||
| 169 | Apply for funding | The Draper Richards Kaplan Foundation seeks to dramatically improve the lives of people and the world around us through innovative strategies, systems changing approaches, and disrupting technologies. Our goal is to find social entrepreneurs with dynamic ideas and nurture them at the early stages with maximum leverage and total commitment. | $300,000 | 3 years | Draper Richards Kaplan | Open Year Round | Not applicable | https://www.drkfoundation.org/apply-for-funding/ | |||
| 170 | A harmonized European forensics approach on drugs analysis | The production of synthetic drugs in the EU is continuously expanding. The laboratories producing synthetic drugs are becoming more professional and versatile, resulting in increased production and greater flexibility in terms of which substances are produced, how they are produced, and how/where they are sold. On the one hand, criminal networks and criminals active in the production of synthetic drugs display a particularly high degree of specialization. Thus, a modern and harmonized European approach to the analysis of the drug's composition would help to crossmatch seized drugs and illegal drug markets to labs and make the links between cases, allowing a cross-border exchange of such evidence. Proposals funded under this topic are expected to engage with the Europol Innovation Lab during the lifetime of the project, including validating the outcomes, with the aim of facilitating future uptake of innovations for the law enforcement community. | EURO 4,500,000 | Not specified | European Commission | 23-Nov-23 | Not applicable | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-cl3-2023-fct-01-02;callCode=null;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1,2,8;statusCodes=31094501;programmePeriod=null;programCcm2Id=n | |||
| 171 | Improving social and societal preparedness for disaster response and health emergencies | This topic requires the effective contribution of SSH disciplines and the involvement of SSH as well as gender experts, and institutions as well as the inclusion of relevant SSH and gender expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities. The involvement of citizens, civil society, and other societal stakeholders in co-design and co-creation should be promoted. In order to achieve the expected outcomes, international cooperation is encouraged. | EURO 4,000,000 | Not specified | European Commission | 23-Nov-23 | Not applicable | https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-cl3-2023-drs-01-01;callCode=null;freeTextSearchKeyword=;matchWholeText=true;typeCodes=1,2,8;statusCodes=31094501;programmePeriod=null;programCcm2Id=n | |||
| 172 | Primary Care-Based Screening Tool and Intervention Development for the Detection and Prevention of Abuse and Neglect in Older and Vulnerable Adults With, or at Risk for, Mild Cognitive Impairment and AD/ADRD (R61/R33 Clinical Trial Required) | The purpose of this Notice of Funding Opportunity (NOFO) is to support research that can lead to the development of primary care-based screening tools and early interventions to detect and prevent abuse and neglect (hereafter referred to as “AN”) in older and vulnerable adults living with, or at risk for, mild cognitive impairment (MCI) and Alzheimer’s disease (AD) and Alzheimer's disease-related dementias (ADRD). In the interest of supporting early-stage research conducted by interdisciplinary teams that can lead to the development of screening tools and behavioral interventions that can be successfully implemented in primary care settings with diverse patient populations, this NOFO invites five-year, R61/R33 phased award applications. | $3,000,000 | 5 years | National Institutes of Health (NIH) | October 20, 2023 | September 20, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-048.html | |||
| 173 | Exploratory Grants for Climate Change and Health Research Center Development (P20 Clinical Trial Optional) | The purpose of this Notice of Funding Opportunity (NOFO) is to solicit P20 planning grant applications for Climate Change and Health Research Centers (CCHRCs). | USD 2,550,000 | 3 years | National Institutes of Health (NIH) | November 07, 2023 | April 1, 2023; October 7, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-23-007.html | |||
| 174 | Toward ElucidAting MechanismS of HIV Pathogenesis within the Mission of the NIDDK (Pathogenesis TEAMS) (R01 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) seeks to support multidisciplinary research teams with complementary expertise in HIV and pathobiology, pathophysiology, and/or metabolism in organs, tissues, and/or biological systems of specific interest to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These teams will comprehensively interrogate fundamental biological mechanisms underlying HIV-associated comorbidities, co-infections, and complications relevant to the mission of the NIDDK and advance progress toward preventing or alleviating them. | USD 500,000 per year | 5 years | National Institute of Health (NIH) | November 15, 2023 | February 15, 2023 and October 15, 2023 | https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-039.html | |||
| 175 | Leveraging Social Networks to Promote Widespread Individual Behavior Change (R01 Clinical Trial Optional) | The purpose of this Notice of Funding Opportunity (NOFO) is to invite basic observational or experimental behavioral and/or social science R01 applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for health. Research supported through this NOFO will examine at least two levels of analysis: interpersonal processes and social network characteristics. Projects will identify targets for future social network health behavior change interventions across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (e.g., populations in mid- to- late life). Basic research to develop, refine, or optimize measures (i.e., assays) of putative targets (e.g., intra/interpersonal mechanisms of behavior change and/or social network characteristics) is also supported by this NOFO. | USD 500,000 | 5 years | National Institutes of Health (NIH) | November 03, 2023 | October 3, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-025.html | |||
| 176 | Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD (R01 Clinical Trial Not Allowed) | This Notice of Funding Opportunity (NOFO) invites innovative R01 applications that explore how structural, community, and interpersonal mechanisms operate over the life course among middle- and older-aged racial and/or ethnic subgroups considered to be a minority in the US to shape health outcomes, and any resulting in health disparities. This NOFO also invites innovative applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer’s disease (AD) and Alzheimer's disease-related dementias (ADRD). High-risk/high-payoff projects that lack preliminary data are more appropriate for the companion NOFO, RFA-AG-24-029, which invites Exploratory/Developmental Research Grant (R21) applications. | $500,000 in per year | 5 years | National Institute of Health (NIH) | November 03, 2023 | October 3, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-028.html | |||
| 177 | Leveraging Social Networks to Promote Widespread Individual Behavior Change (R34 Clinical Trial Optional) | This Notice of Funding Opportunity (NOFO) invites R34 applications to support the planning activities necessary to develop social network interventions to promote health across the lifespan, especially in populations in which they are currently largely underdeveloped and untested (such as populations in mid- and late-life). Applications suited to this R34 will focus on planning activities for social network interventions for which a target interpersonal process of behavior change or social network characteristic has already been identified. Planning activities are those activities that are expected to yield necessary and sufficient information to inform final decisions about a social network health behavior change intervention prior to instigation of a hypothesis-driven trial to test a social network intervention. Activities may include but are not limited to, team-building, protocol development, piloting of systems for data collection and/or management, feasibility and acceptability testing, staff training, and establishing documentation procedures | USD 450,000 | 3 years | National Institutes of Health (NIH) | November 03, 2023 | October 3, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-026.html | |||
| 178 | Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (R34 Clinical Trial Not Allowed) | The goal of this Notice of Funding Opportunity (NOFO) is to seek applications proposing a set of planning activities that will lay the groundwork for scientific projects aimed at using animal models and longitudinal research designs to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. This funding opportunity will support projects of limited scope focused on the coordination of a multidisciplinary research team; development of the research framework, design, and approach; and activities that will establish feasibility, validity, and/or other technically qualifying results that, if successful, would support a competitive application for a larger-scale, definitive research project (e.g., R01). | $450,000 | 2 years | National Institutes of Health (NIH) | November 09, 2023 | October 10, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-019.html | |||
| 179 | Data Integration and Statistical Analysis Methods (DISAM) (U01 Clinical Trial Not Allowed) | This Notice of Funding Opportunity (NOFO) solicits applications to develop innovative and generalizable statistical and computational methods for the analysis of data from the human Developmental Genotype-Expression (dGTEx) and non-human primate (NHP dGTEx) projects. Methods that assess the influence of genetic variation on development, compare gene expression and regulation across tissues and time points, or leverage comparative genomics to understand developmental and evolutionary processes and integrate with existing tissue and cell atlas efforts are strongly encouraged. This NOFO is open to all applicants regardless of whether they are currently affiliated with dGTEx, NHP dGTEx, or neither | $400K per year | 3 years | National Institutes of Health (NIH) | November 20, 2023 | October 20, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-23-005.html | |||
| 180 | Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required) | The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies involving humans to expand our knowledge of the interrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. | $300,000 per year | 5 years | National Institutes of Health (NIH) | November 13, 2023 | October 13, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-021.html | |||
| 181 | Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required) | The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies involving humans to expand our knowledge of the interrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. | $300,000 per year | 5 years | National Institutes of Health (NIH) | November 13, 2023 | October 13, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-021.html | |||
| 182 | Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed | The purpose of this Notice of Funding Opportunity (NOFO) is to support research project applications to expand our knowledge on the basic neurobiology of the interrelationship between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics. | $300,000 per year | 5 years | National Institutes of Health (NIH) | November 13, 2023 | October 13, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-020.html | |||
| 183 | Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. | $300,000 per year | 3 years | National Institute of Health (NIH) | November 17, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-015.html | |||
| 184 | Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of IBD susceptibility loci, causal variants and effector genes, and IBD-related phenotypes and physiological domains under investigation via Ancillary Studies utilizing the extensive resources, including subjects, samples and datasets, established by the IBDGC. Proposed Ancillary Studies should focus on causal variant identification and/or functional characterization of effector genes within IBD risk loci and must not duplicate studies that are either ongoing or already completed by the IBDGC. | $300,000 per year | 3 years | National Institute of Health (NIH) | November 08, 2023 | 30 days before application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-023.html | |||
| 185 | Biomedical Research Project Grants | Biomedical Research Project Grants are committed to playing a pivotal role in ending MND. The biomedical research programme is delivering significant and measurable advances in understanding and treating the disease. They only fund research of the highest scientific excellence and greatest relevance to MND. | £285,000 | 3 years | Motor Neurone Disease Association | 27 Oct 23 | Not Applicable | https://www.mndassociation.org/app/uploads/2019/10/Project-Grant-Guidelines-Summary-Application-Nov-19.pdf | |||
| 186 | Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD(R21 Clinical Trial Not Allowed) | This Notice of Funding Opportunity (NOFO) invites innovative R21 applications that explore how structural, community, and interpersonal mechanisms operate over the life course among middle- and older-aged racial and/or ethnic subgroups considered to be a minority in the US to shape health outcomes, and any resulting in health disparities. This NOFO also invites innovative applications that explore data needs and methods when studying the effect of immigration on life-course health, including Alzheimer’s disease (AD) and Alzheimer's disease-related dementias (ADRD). Applications with preliminary data are encouraged to apply to companion NOFO RFA-AG-24-028, which invites Research Project Grant (R01) applications. However, high-risk/high-payoff projects that lack preliminary data may be more appropriate for this NOFO. | $275,000 | 2 years | National Institute of Health (NIH) | November 03, 2023 | October 3, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-24-029.html | |||
| 187 | NIH Blueprint for Neuroscience Research: Tools and Technologies to Explore Nervous System Biomolecular Condensates (R21 Clinical Trial Not Allowed) | The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. The purpose of this FOA is to support the development of innovative tools and/or technologies to monitor or manipulate biomolecular condensates (BMCs) in vivo and enable investigators to adopt these tools to answer outstanding questions in basic neuroscience. This research will transform our understanding of the mechanistic role of BMCs in human nervous system health and disease and may serve as the foundation for the development of novel BMC-based therapeutics | USD 275,000 | 2 years | National Institutes of Health (NIH) | November 14, 2023 | October 14, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-039.html | |||
| 188 | Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. | $275,000 | 2 years | National Institute of Health (NIH) | November 17, 2023 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-23-014.html | |||
| 189 | Developing Measures to Advance Access and Quality in Global Mental Health Services (R34 Clinical Trial Not Allowed) | NIMH seeks applications to support the development and pilot testing of outcomes-focused access and quality metrics in global mental health services research that could be reviewed, approved, and implemented by the relevant regulatory or governing domestic bodies of the country or countries where the research takes place. NIMH is interested in studies that take a theory-driven, empirical, and culturally appropriate approach to developing and testing measures utilizing real-world data. This Notice of Funding Opportunity (NOFO) aims to advance the development of novel and innovative research to assess outcomes mediated through changes in access to mental health care and quality of care across programs or clinical settings. | USD 225,000 per year | 3 years | National Institutes of Health (NIH) | October 18, 2023 | September 18, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-23-300.html | |||
| 190 | NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) | This NIDCR Small Grant Program for New Investigators supports basic and clinical research conducted by scientists who are in the early stages of establishing an independent research career in oral, dental and craniofacial research. This R03 program supports pilot or feasibility studies and developmental research projects with the intention of obtaining sufficient preliminary data for a subsequent investigator initiated Research Project Grant (R01) or equivalent application. | $200,000 | two years | National Institute of Health (NIH) | October 16 2023 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-084.html | |||
| 191 | International Capacity Building Fund | The purpose of the International Capacity Building (ICB) Fund is to provide resources to enhance education and training of applied microbiology in developing countries. | British Pounds 5,000 | Not specified | Society for Applied Microbiology | 10-Nov-23 | Not Applicable | https://appliedmicrobiology.org/publishing-resources/grants-awards/international-capacity-building-fund.html | |||
| 192 | Ignacio H. de Larramendi Research Grants | Fundación MAPFRE wants to promote research projects related to two areas of action, health promotion and insurance, and social protection, by opening a new call for Ignacio H. de Larramendi Research Grants for a total value of 300,000 euros. Interested applicants are expected to choose their field of action (Health Promotion or Insurance and Social Protection), prepare the documentation related to their project (using this template for the explanatory memorandum), and submit the application. These grants are intended to support the work of researchers or research teams in the academic and professional fields, who wish to develop research programs in the aforementioned areas, independently or within the framework of universities, hospitals, companies, or research centres to which they are attached. | 30,000 euros | 1 year | Fundación MAPFRE | October 17, 2023 | Not applicable | https://www.fundacionmapfre.org/en/awards-aids/ignacio-larramendi-research-grants/ | |||
| 193 | Advancing Development of Diagnostics for Congenital and Adult Acquired Syphilis (R21 Clinical Trial Not Allowed) | The purpose of this Notice of Funding Opportunity (NOFO) is to promote research to rapidly move promising technologies through the product development pipeline towards the development of new diagnostics for syphilis. Translational diagnostic development research which includes the collection and use of clinical samples is allowed, however clinical trials are not allowed. Applications concerning congenital syphilis would be of highest programmatic priority but efforts on adult acquired syphilis diagnosis are eligible. | $275,000 | 2 years | National Institutes of Health (NIH) | November 02, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-039.html | |||
| 194 | Analysis of data in the COVID-19 Neuro Databank-Biobank (R03 - Clinical Trial Not Allowed) | The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVID Project). The NeuroCOVID Project was established in 2020 to serve as a robust national resource to understand the neurological complications associated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications of COVID-19 by using this de-identified database. The data may be combined with data from other U.S. and International databases for analyses. However, collection of new primary data from those affected by COVID-19 or comparison cohorts is NOT covered by this NOFO. | $50,000 per year | 2 years | National Institutes of Health (NIH) | November 08, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-025.html | |||
| 195 | HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) | The National Institutes of Health (NIH) is inviting applications for this Exploratory/Developmental Phased Award Cooperative Agreement. The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. | USD 1,500,000 | 5 years | National Institutes of Health (NIH) | October 23, 2023 | 30 days prior to application due date | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-018.html | |||
| 196 | Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) | The National Institutes of Health (NIH) is inviting applications for this Research Project Grant. This Funding Opportunity Announcement (FOA) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes. | $1,000,000 per year | 3 years | National Institute of Health (NIH) | October 26, 2023 | January 28, 2023 and September 26, 2023 | https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-021.html | |||
| 197 | Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) for R34 planning grant applications focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and incidence of FASD and (2) interventions for FASD. | $450,000 | 3 years | National Institutes of Health (NIH) | October 17, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-097.html | |||
| 198 | Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional) | This Funding Opportunity Announcement (FOA) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this FOA is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials | $350,000 | 3 years | National Institutes of Health (NIH) | October 17, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-098.html | |||
| 199 | Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods. | $325,000 per year | 2 years | National Institutes of Health (NIH) | October 18, 2023 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-360.html | |||
| 200 | Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed) | These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. | USD 275,000 | 2 years | National Institute of Health (NIH) | October 16, 2023 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-21-323.html | |||
| 201 | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States. | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023 | Not applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-084.html | |||
| 202 | Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed) | The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility | $275,000 | 2 years | National Institutes of Health (NIH) | October 16, 2023 | Not Applicable | https://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html | |||
| 203 | Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) | The purpose of this FOA is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). | Application budgets are not limited | 3 years | National Institutes of Health (NIH) | October 17, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-136.html | |||
| 204 | BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users | Not Specified | 4 years. | National Institute of Health (NIH) | October 27, 2023. | 60 days prior to the receipt date | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-027.html | |||
| 205 | BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) | to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions | not specified | 3years | National Institute of Health (NIH) | October 27, 2023 | Not applicable | https://grants.nih.gov/grants/guide/rfa-files/RFA-EY-21-001.html | |||
| 206 | HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) | The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads to Phase I clinical trials and readiness for the Early Phase Pain Investigation Clinical Network (EPPIC-Net) https://heal.nih.gov/research/clinical-research/eppic-net or other Phase II clinical studies. | Budget is not limited | 5 years | National Institute of Health (NIH) | October 17, 2023 | 30 days prior to receipt date. | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-010.html | |||
| 207 | BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) | This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research. | Application budgets are not limited | 3 years. | National Institute of Health (NIH) | October 27, 2023 | 60 days prior to the receipt date. | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-026.html | |||
| 208 | Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional) | The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. | Application budgets are not limited | 4 to 5 years | National Institute of Health (NIH) | October 18, 2023 | 60 days prior to the application due date. | https://grants.nih.gov/grants/guide/pa-files/PAR-21-315.html?utm_medium=email&utm_source=govdelivery | |||
| 209 | Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional) | This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects with low- and middle-income country (LMIC) institutions/ scientists on brain and other nervous system function and disorders throughout life, relevant to LMICs. | Application budgets are not limited | 5 years | National Institute of Health (NIH) | November 15, 2023 | 30 days prior to the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-311.html | |||
| 210 | Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). | Refer to other award budget information | 5 years. | National Institute of Health (NIH) | November 3, 2023 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-252.html | |||
| 211 | Emerging Global Leader Award (K43 Independent Clinical Trial Required) | This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors. | Refer to other award budget information | 5 years. | National Institute of Health (NIH) | November 3, 2023 | 30 days before the application due date | https://grants.nih.gov/grants/guide/pa-files/PAR-21-251.html | |||
Tag:Fellowship, Scholarships
